Jean Terrier

Dr. Jean Terrier


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CLCamille Lenoir
Camille Lenoir
JTJean Terrier
Jean Terrier
YGYvonne Gloor
Yvonne Gloor
PGPauline Gosselin
Pauline Gosselin
Daali YoussefDaali Youssef
Daali Youssef
VRVictoria Rollason
Victoria Rollason
Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the increased use of DOACs in real-world settings, safety and efficacy concerns have emerged, particularly regarding their concomitant use with other drugs. Increasing evidence highlights drug–drug interactions with CYP3A/P-gp modulators leading to adverse events. However, current recommendations for dose adjustment do not consider CYP3A/P-gp genotype and phenotype. We aimed to determine their impact on apixaban and rivaroxaban blood exposure. Three-hundred hospitalized patients were included. CYP3A and P-gp phenotypic activities were assessed by the metabolic ratio of midazolam and AUC0–6h of fexofenadine, respectively. Relevant CYP3A and ABCB1 genetic polymorphisms were also tested. Capillary blood samples collected at four time-points after apixaban or rivaroxaban administration allowed the calculation of pharmacokinetic parameters. According to the developed multivariable linear regression models, P-gp activity (p < 0.001) and creatinine clearance (CrCl) (p = 0.01) significantly affected apixaban AUC0–6h. P-gp activity (p < 0.001) also significantly impacted rivaroxaban AUC0–6h. The phenotypic switch (from normal to poor metabolizer) of P-gp led to an increase of apixaban and rivaroxaban AUC0–6h by 16% and 25%, respectively, equivalent to a decrease of 38 mL/min in CrCl according to the apixaban model. CYP3A phenotype and tested SNPs of CYP3A/P-gp had no significant impact. In conclusion, P-gp phenotypic activity, rather than known CYP3A/P-gp polymorphisms, could be relevant for dose adjustment.

1 August 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
JTJean Terrier
Jean Terrier
FGFrédéric Gaspar
Frédéric Gaspar
PFPierre Fontana
Pierre Fontana
Daali YoussefDaali Youssef
Daali Youssef
JRJean-Luc Reny
Jean-Luc Reny
CSCaroline F. Samer
Caroline F. Samer

9 June 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JTJean Terrier
Jean Terrier
FGFrédéric Gaspar
Frédéric Gaspar
MGMonia Guidi
Monia Guidi
PFPierre Fontana
Pierre Fontana
YDYoussef Daali
Youssef Daali
JRJean‐Luc Reny
Jean‐Luc Reny
Available data have shown an association between direct oral anticoagulant (DOAC) plasma concentration and clinical, particularly bleeding, events. Factors that may influence DOAC plasma concentration are therefore the focus of particular attention. Population pharmacokinetic (PopPK) analyses can help in identifying such factors while providing predictive models. The main aim of the present study was to identify all the PopPK models to date for the four most frequently used DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban). The secondary aim was to use these models to simulate different DOAC plasma concentration–time profiles in relevant clinical scenarios. The results of our model‐based simulations confirm the clinical relevance of the known major factors influencing DOAC exposure and support the current approved dose adaptation, at least for atrial fibrillation. They also highlight how the accumulation of covariates, not currently considered for dose adaptation due to their seemingly minor influence on DOAC exposure, lead to supratherapeutic blood concentrations and could thus enhance the risk of major bleeding. The present results therefore question DOAC dose adaptation in the presence of these covariates, such as drug–drug interaction or genotypes, alongside the known existing covariates. As the overall effect of accumulation of several covariates could be difficult to apprehend for the clinicians, PopPK modeling could represent an interesting approach for informed precision dosing and to improve personalized prescription of DOACs.

4 October 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
JTJean Terrier
Jean Terrier
FGFrédéric Gaspar
Frédéric Gaspar
PGPauline Gosselin
Pauline Gosselin
OROlivier Raboud
Olivier Raboud
CLCamille Lenoir
Camille Lenoir
FGfor the OptimAT study group
for the OptimAT study group
When used in real‐world conditions, substantial interindividual variations in direct oral anticoagulant (DOAC) plasma concentrations are observed for a given dose, leading to a risk of over‐ or under‐exposure and clinically significant adverse events. Physiologically‐based pharmacokinetic (PBPK) models could help physicians to tailor DOAC prescriptions in vulnerable patient populations, such as those in the hospital setting. The present study aims to validate prospectively PBPK models for rivaroxaban and apixaban in a large cohort of elderly, polymorbid, and hospitalized patients. In using a model of geriatric population integrating appropriate physiological parameters into models first optimized with healthy volunteer data, observed plasma concentration collected in hospitalized patients on apixaban (n = 100) and rivaroxaban (n = 100) were adequately predicted (ratio predicted/observed area under the concentration curve for a dosing interval [AUCtau] = 0.97 [0.96–0.99] geometric mean, 90% confidence interval, ratio predicted/observed AUCtau = 1.03 [1.02–1.05]) for apixaban and rivaroxaban, respectively. Validation of the present PBPK models for rivaroxaban and apixaban in in‐patients represent an additional step toward the feasibility of bedside use.

15 September 2023 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
JTJean Terrier
Jean Terrier
AMAmélie Mach
Amélie Mach
PFPierre Fontana
Pierre Fontana
FBFanny Bonhomme
Fanny Bonhomme
ACAlessandro Casini
Alessandro Casini
Introduction: Despite clear, relatively easy-to-use guidance, many clinicians find the preoperative management of direct oral anticoagulants (DOACs) challenging. Inappropriate management can delay procedures and lead to haemorrhagic or thromboembolic complications. We aimed to describe preoperative management practices regarding DOACs in a tertiary hospital and clinicians’ adherence to in-house recommendations. Method: We included all patients being treated with DOACs who underwent elective surgery in 2019 and 2020 (n = 337). In-house recommendations for perioperative management were largely comparable to the 2022 American College of Chest Physicians guidelines. Results: Typical patients were older adults with multiple comorbidities and high thrombotic risk stratification scores, and 65.6% (n = 221) had not undergone recommended preoperative anticoagulation management protocols. Patients operated on using local anaesthesia (adjusted OR = 0.30, 95%CI 0.14–0.66; p < 0.01) were less likely to have been treated following institutional recommendations, but no association between their procedure’s bleeding risk and adherence was found. Clinicians’ failures to adhere to recommendations mostly involved late or non-indicated interruptions of anticoagulation treatment (n = 89, 26.4%) or inappropriate heparin bridging (n = 54, 16.0%). Forty-five (13.3%) procedures had to be postponed. Incorrect preoperative anticoagulation management was directly responsible for 12/45 postponements (26.7% of postponements). Conclusion: This study highlights clinicians’ low adherence rates to institutional recommendations for patients treated with DOACs scheduled for elective surgery in a tertiary hospital centre. To the best of our knowledge, this is the first clinical study addressing the issue of clinicians’ adherence to guidelines for the preoperative management of DOACs. Going beyond the issue of whether clinicians are knowledgeable about guidelines or have them available, this study questions how generalisable guidelines are in a tertiary hospital managing many highly polymorbid patients. Further studies should identify the causes of poor adherence.

4 March 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
FGFrédéric Gaspar
Frédéric Gaspar
JTJean Terrier
Jean Terrier
CJCelestin Jacot‐Descombes
Celestin Jacot‐Descombes
PGPauline Gosselin
Pauline Gosselin
VAValentine Ardoino
Valentine Ardoino
FGfor the OptimAT study group
for the OptimAT study group
Aims: In a large cohort of hospitalized patients, previously validated physiologically based pharmacokinetic (PBPK)‐based models for apixaban and rivaroxaban are being assessed for their performance in predicting individual pharmacokinetics, aiming to identify patients at high risk of under‐ or overdosing based on demographic, physiological and CYP‐related phenotypic characteristics. Methods: Clinical data were collected from hospitalized patients treated with apixaban ( n = 100) or rivaroxaban ( n = 100) at the Geneva University Hospitals (HUG). These patients were recruited in the OptimAT trial (NCT03477331). PBPK modelling created virtual twins for each patient, integrating demographic, kidney function, P‐glycoprotein (Pgp) and cytochrome P450 (CYP450) 3A phenotyping. Individual PK profiles were simulated for every patient and compared to actual drug exposure, as assessed with LC/MS–MS. Results: Mean fold error (MFE) (95% CI) for the apixaban and rivaroxaban models integrating demographic and kidney function was within the pre‐required bioequivalency criteria with 1.10 (1.04–1.16) and 0.97 (0.93–1.02), respectively. Adding individual Pgp and CYP3A phenotypes led to a slight overprediction 1.25 (1.17–1.33) and 1.30 (1.21–1.39), but patients at risk for bleeding were correctly predicted with MFEs of 0.90 (0.76–1.04) and 1.15 (1.11–1.20). Conclusions: In a large cohort of hospitalized patients, a PBPK model incorporating demographic characteristics and kidney function can accurately predict, within bioequivalency criteria, an individual's apixaban and rivaroxaban plasma exposure. The added value of individual Pgp and 3A phenotypes on the predictive performance need to be further explored, although patients at higher risk for bleeding may benefit. This innovative approach represents an important step towards the application of PBPK at bedside.